Glipizide: Side Effects, Uses & Monitoring
Glipizide extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- Data source
- FDA labeling via NIH DailyMed (label 04fad2a9…)
- Label version
- current
- Last reviewed
- 2026
Reported adverse reactions
Reactions listed in current FDA labeling, with the highest frequency reported across summarized placebo-controlled trials.
| Adverse reaction (as reported in labeling) | Reported frequency* |
|---|---|
| Asthenia | 13% |
| Headache | 8.7% |
| Dizziness | 6.8% |
| Diarrhea | 5.4% |
| Nervousness | 3.6% |
| Tremor | 3.6% |
| Flatulence | 3.2% |
*Highest percentage reported for the active moiety across placebo-controlled trial tables in current FDA labeling. Values reflect trial reporting, not your individual risk.
Labeled uses (from FDA prescribing information)
Glipizide extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Tests providers may use to monitor Glipizide therapy
Conditions associated with Glipizide in labeling
Frequently Asked Questions
What is Glipizide used for?
FDA labeling lists the approved uses shown above under "Labeled uses." This summary is informational; only a qualified prescriber can determine whether a medication is appropriate for you.
What are the most commonly reported side effects of Glipizide?
The table above shows adverse reactions and the highest frequencies reported in placebo-controlled trials summarized in current FDA labeling for Glipizide. Individual risk varies.
Does Glipizide require lab monitoring?
Labeling and standard practice associate Glipizide with periodic laboratory monitoring; the tests above are commonly ordered by clinicians to monitor patients on therapy. Your provider decides what is appropriate.
Where does this information come from?
All clinical facts on this page were extracted from the current FDA-registered product labeling for this ingredient, published by manufacturers through NIH DailyMed. See the source link below.
Medical disclaimer: Educational content extracted from public FDA labeling. Not medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication.